| Market Cap | 57.85M | P/E | - | EPS this Y | 41.60% | Ern Qtrly Grth | - |
| Income | -45.61M | Forward P/E | -1.39 | EPS next Y | 11.10% | 50D Avg Chg | 3.00% |
| Sales | 21.48M | PEG | -0.11 | EPS past 5Y | - | 200D Avg Chg | -11.00% |
| Dividend | N/A | Price/Book | 0.82 | EPS next 5Y | 17.00% | 52W High Chg | -50.00% |
| Recommedations | 2.00 | Quick Ratio | 2.66 | Shares Outstanding | 6.35M | 52W Low Chg | 44.00% |
| Insider Own | 31.62% | ROA | -34.72% | Shares Float | 3.84M | Beta | 0.65 |
| Inst Own | 18.55% | ROE | -101.78% | Shares Shorted/Prior | 23.10K/10.28K | Price | 1.11 |
| Gross Margin | -132.62% | Profit Margin | -212.33% | Avg. Volume | 104,867 | Target Price | 35.50 |
| Oper. Margin | -143.01% | Earnings Date | Nov 6 | Volume | 75,741 | Change | 1.83% |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
| HC Wainwright & Co. | Neutral | Jun 20, 24 |
| HC Wainwright & Co. | Neutral | Jun 13, 24 |
| HC Wainwright & Co. | Neutral | Apr 1, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Schornstein Alexander | 10% Owner 10% Owner | Jan 17 | Buy | 0.79 | 645,080 | 509,613 | 8,209,372 | 01/19/24 |
| Okazaki Jason A | CEO and President CEO and President | Aug 02 | Sell | 1.0879 | 11,827 | 12,867 | 164,786 | 08/03/23 |
| McHutchison John G | Director Director | May 22 | Sell | 1.04 | 25,972 | 27,011 | 169,160 | 05/24/23 |
| Bjorkquist Jeanette M | Principal Accounting.. Principal Accounting Officer | May 22 | Sell | 1.04 | 274 | 285 | 27,532 | 05/24/23 |
| Delaney William E IV | Chief Scientific Off.. Chief Scientific Officer | May 22 | Sell | 1.04 | 6,561 | 6,823 | 116,437 | 05/24/23 |
| Okazaki Jason A | CEO and President CEO and President | May 22 | Sell | 1.04 | 6,561 | 6,823 | 126,613 | 05/24/23 |
| McHutchison John G | Director Director | Mar 30 | Sell | 0.8232 | 14,883 | 12,252 | 177,632 | 03/31/23 |
| Bjorkquist Jeanette M | Principal Accounting.. Principal Accounting Officer | Feb 16 | Sell | 0.82 | 774 | 635 | 23,806 | 03/31/23 |
| Delaney William E IV | Chief Scientific Off.. Chief Scientific Officer | Mar 29 | Sell | 0.8232 | 3,421 | 2,816 | 85,498 | 03/31/23 |
| McHutchison John G | Chief Executive Offi.. Chief Executive Officer | Aug 08 | Sell | 2.1277 | 12,314 | 26,200 | 192,515 | 08/10/22 |
| Samar Michael P. | Chief Financial Offi.. Chief Financial Officer | Jul 25 | Sell | 2.2174 | 2,020 | 4,479 | 77,228 | 07/26/22 |
| Delaney William E IV | Chief Scientific Off.. Chief Scientific Officer | May 31 | Sell | 1.9224 | 4,164 | 8,005 | 76,419 | 06/02/22 |
| Samar Michael P. | Chief Financial Offi.. Chief Financial Officer | Mar 29 | Sell | 2.17 | 2,285 | 4,958 | 76,748 | 03/31/22 |
| Stamm Luisa M | Chief Medical Office.. Chief Medical Officer | Mar 29 | Sell | 2.17 | 1,038 | 2,252 | 40,315 | 03/31/22 |
| Delaney William E IV | Chief Scientific Off.. Chief Scientific Officer | Mar 29 | Sell | 2.17 | 1,038 | 2,252 | 78,083 | 03/31/22 |
| Okazaki Jason A | Chief Operating Offi.. Chief Operating Officer | Mar 29 | Sell | 2.17 | 1,269 | 2,754 | 94,614 | 03/31/22 |
| McHutchison John G | CEO and President CEO and President | Mar 29 | Sell | 2.17 | 4,614 | 10,012 | 204,829 | 03/31/22 |
| Okazaki Jason A | Chief Operating Offi.. Chief Operating Officer | Mar 28 | Sell | 2.2445 | 4,617 | 10,363 | 64,633 | 03/29/22 |